Other Cancer Clinical Trials
The effects of the drug aflibercept on the measurements (QTc interval) of ECG tests in cancer patients (SLHN 2009-21; Sanofi Aventis TES10897 (Qutie))
Purpose
The primary objective of this study is to evaluate the effects of the drug aflibercept on the measurements (QTc interval) of ECG tests in cancer patients.
Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) criteria, clinical safety and pharmakokinetic (PK, or how the body uses or processes the drug) criteria.
Eligibility Criteria
-
Solid cancerous tumor for which treatment with single-agent docetaxel (administered every 3 weeks, at a dose based on height and weight) is planned
-
Written informed consent
-
Patient has not received more than 2 prior regimens of chemotherapy
-
Does not have conditions that will make it difficult to interpret screening ECGs. This includes, but is not limited to certain types of abnormal heart rhythms or having a pacemaker
-
The initial ECG will be evaluated for eligibility
Final eligibility is determined by the research staff.
Effectiveness of AVE5026 in comparison with injections of placebo in the prevention of venous thromboembolism in cancer patients who are undergoing chemotherapy (SLHN 2008-57; EFC6521 VTE)
Purpose
The primary purpose is to find how well once daily injections of AVE5026 works in comparison with injections of placebo in the prevention of venous thromboembolism (VTE or a blood clot occurring in the veins that breaks off and travels in the bloodstream until it becomes stuck in and blocks a smaller vessel) in cancer patients who are at high risk for VTE and who are undergoing chemotherapy.
The study treatment duration is variable depending on the duration of chemotherapy.
Eligibility Criteria
-
Cancer patients with metastatic or advanced stage solid tumor of lung, pancreas, stomach, colon/rectum, bladder or ovary
-
Initiating a new course of chemotherapy with a minimum intent of 3 months therapy
-
No need for anti-clotting drugs or devices for known clots
-
No patients at high risk of bleeding
-
No severe kidney problems
Final eligibility is determined by the research staff.